Ticagrelor/Aspirin

替格瑞洛/阿司匹林

Report date: 2023/08/18 20:01:02

Base Information

Drug NameTicagrelor/Aspirin
Drug Alias Name替格瑞洛阿司匹林胶囊
ClassificationSmall molecules
Mechanisms of ActionPurinergic receptor P2Y12 antagonistsCyclooxygenases inhibitors
TargetsPurinergic receptor P2Y12Cyclooxygenases
Therapy Area/IndicationsAcute Coronary SyndromeStrokeIschemic Attack, Transient
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes TicagrelorAspirin
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLepu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLepu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAcute Coronary SyndromeStrokeIschemic Attack, Transient
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A